Literature DB >> 22854659

Inter-tumor heterogeneity.

Mike Cusnir1, Ludmila Cavalcante.   

Abstract

Advances in the molecular study of cancer have focused on biomarkers in the setting of tumor-driving mutations within the great heterogeneity of the tumor genomic landscape. It is clearly recognized now that even two tumors originating from the same organ even if histological they appear similar their behavior and response to therapy can be different. These findings have increased interest and research to find truly prognostic and predictive biomarkers to serve as tools in better assessing the natural course of disease and response to treatments in the hope of truly individualizing cancer therapy in the future.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22854659      PMCID： PMC3551890          DOI： 10.4161/hv.21203

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  8 in total

1.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Authors:  Wendy De Roock; Bart Claes; David Bernasconi; Jef De Schutter; Bart Biesmans; George Fountzilas; Konstantine T Kalogeras; Vassiliki Kotoula; Demetris Papamichael; Pierre Laurent-Puig; Frédérique Penault-Llorca; Philippe Rougier; Bruno Vincenzi; Daniele Santini; Giuseppe Tonini; Federico Cappuzzo; Milo Frattini; Francesca Molinari; Piercarlo Saletti; Sara De Dosso; Miriam Martini; Alberto Bardelli; Salvatore Siena; Andrea Sartore-Bianchi; Josep Tabernero; Teresa Macarulla; Frédéric Di Fiore; Alice Oden Gangloff; Fortunato Ciardiello; Per Pfeiffer; Camilla Qvortrup; Tine Plato Hansen; Eric Van Cutsem; Hubert Piessevaux; Diether Lambrechts; Mauro Delorenzi; Sabine Tejpar
Journal:  Lancet Oncol       Date:  2010-07-08       Impact factor: 41.316

2.  Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

Authors:  Gordon Hutchins; Katie Southward; Kelly Handley; Laura Magill; Claire Beaumont; Jens Stahlschmidt; Susan Richman; Philip Chambers; Matthew Seymour; David Kerr; Richard Gray; Philip Quirke
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

3.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Authors:  Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger
Journal:  N Engl J Med       Date:  2003-07-17       Impact factor: 91.245

4.  PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

Authors:  Fotios Loupakis; Luca Pollina; Irene Stasi; Annamaria Ruzzo; Mario Scartozzi; Daniele Santini; Gianluca Masi; Francesco Graziano; Chiara Cremolini; Eliana Rulli; Emanuele Canestrari; Niccola Funel; Gaia Schiavon; Iacopo Petrini; Mauro Magnani; Giuseppe Tonini; Daniela Campani; Irene Floriani; Stefano Cascinu; Alfredo Falcone
Journal:  J Clin Oncol       Date:  2009-04-27       Impact factor: 44.544

5.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

6.  The genomic landscapes of human breast and colorectal cancers.

Authors:  Laura D Wood; D Williams Parsons; Siân Jones; Jimmy Lin; Tobias Sjöblom; Rebecca J Leary; Dong Shen; Simina M Boca; Thomas Barber; Janine Ptak; Natalie Silliman; Steve Szabo; Zoltan Dezso; Vadim Ustyanksky; Tatiana Nikolskaya; Yuri Nikolsky; Rachel Karchin; Paul A Wilson; Joshua S Kaminker; Zemin Zhang; Randal Croshaw; Joseph Willis; Dawn Dawson; Michail Shipitsin; James K V Willson; Saraswati Sukumar; Kornelia Polyak; Ben Ho Park; Charit L Pethiyagoda; P V Krishna Pant; Dennis G Ballinger; Andrew B Sparks; James Hartigan; Douglas R Smith; Erick Suh; Nickolas Papadopoulos; Phillip Buckhaults; Sanford D Markowitz; Giovanni Parmigiani; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein
Journal:  Science       Date:  2007-10-11       Impact factor: 47.728

7.  Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer.

Authors:  W Ichikawa; T Takahashi; K Suto; T Yamashita; Z Nihei; Y Shirota; M Shimizu; Y Sasaki; R Hirayama
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

Review 8.  Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Authors:  Salvatore Siena; Andrea Sartore-Bianchi; Federica Di Nicolantonio; Julia Balfour; Alberto Bardelli
Journal:  J Natl Cancer Inst       Date:  2009-09-08       Impact factor: 13.506
  8 in total
  12 in total

1.  Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2-negative breast cancer patients treated with docetaxel.

Authors:  Sreenath M Krishnan; Sofiene S Laarif; Brendan C Bender; Angelica L Quartino; Lena E Friberg
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-05-02

2.  Orthotopic Versus Allotopic Implantation: Comparison of Radiological and Pathological Characteristics.

Authors:  YeYu Cai; TaiLi Chen; JiaYi Liu; ShuHui Peng; Huan Liu; Min Lv; ZhuYuan Ding; ZiYi Zhou; Lan Li; Shan Zeng; EnHua Xiao
Journal:  J Magn Reson Imaging       Date:  2021-10-05       Impact factor: 5.119

3.  Expressional Subpopulation of Cancers Determined by G64, a Co-regulated Module.

Authors:  Jae-Woong Min; Sun Shim Choi
Journal:  Genomics Inform       Date:  2015-12-31

Review 4.  Computational approaches for the identification of cancer genes and pathways.

Authors:  Christos M Dimitrakopoulos; Niko Beerenwinkel
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2016-11-11

5.  Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin.

Authors:  Harvey I Pass; Carmencita Lavilla; Claudia Canino; Chandra Goparaju; Jordan Preiss; Samrah Noreen; Giovanni Blandino; Mario Cioce
Journal:  Oncotarget       Date:  2016-08-30

6.  Inter-Tumor Heterogeneity-Melanomas Respond Differently to GM-CSF-Mediated Activation.

Authors:  Adi Moshe; Sivan Izraely; Orit Sagi-Assif; Sapir Malka; Shlomit Ben-Menachem; Tsipi Meshel; Metsada Pasmanik-Chor; Dave S B Hoon; Isaac P Witz
Journal:  Cells       Date:  2020-07-13       Impact factor: 6.600

7.  Single-cell transcriptional profiling reveals the heterogenicity in colorectal cancer.

Authors:  Weier Dai; Fangbin Zhou; Donge Tang; Liewen Lin; Chang Zou; Wenyong Tan; Yong Dai
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

Review 8.  Cancer vaccines: are we there yet?

Authors:  Michael G Hanna
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

9.  Identification of Distinct Tumor Subpopulations in Lung Adenocarcinoma via Single-Cell RNA-seq.

Authors:  Jae-Woong Min; Woo Jin Kim; Jeong A Han; Yu-Jin Jung; Kyu-Tae Kim; Woong-Yang Park; Hae-Ock Lee; Sun Shim Choi
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

10.  Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology.

Authors:  Marianna A Zolotovskaia; Maxim I Sorokin; Ivan V Petrov; Elena V Poddubskaya; Alexey A Moiseev; Marina I Sekacheva; Nicolas M Borisov; Victor S Tkachev; Andrew V Garazha; Andrey D Kaprin; Peter V Shegay; Alf Giese; Ella Kim; Sergey A Roumiantsev; Anton A Buzdin
Journal:  Int J Mol Sci       Date:  2020-02-26       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.